Research Article: A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Intravenous Formulation of Meloxicam (QP) in Healthy Chinese Subjects
Abstract:
Pain and inflammation are common symptoms of many diseases and can greatly impact a patient’s quality of life., Non-steroidal anti-inflammatory drugs (NSAIDs) can help alleviate these symptoms by inhibiting the activity of regulatory enzymes such as cyclooxygenase (COX) which are responsible for the synthesis of prostaglandin. Meloxicam is a COX- inhibitor, widely used to treat rheumatoid arthritis, osteoarthritis, as well as various pain syndromes., Its selectivity for COX- over COX- within the therapeutic dose range means that meloxicam only reduces prostaglandin at the site of inflammation but does not significantly affect the physiological prostaglandin synthesis, resulting in fewer gastrointestinal adverse effects compared to non-selective NSAIDs. Meloxicam is available in tablet form around the world with good market value and was approved for marketing in China in (Mobic?, . mg tablets).
Introduction:
Pain and inflammation are common symptoms of many diseases and can greatly impact a patient’s quality of life. , Non-steroidal anti-inflammatory drugs (NSAIDs) can help alleviate these symptoms by inhibiting the activity of regulatory enzymes such as cyclooxygenase (COX) which are responsible for the synthesis of prostaglandin. Meloxicam is a COX- inhibitor, widely used to treat rheumatoid arthritis, osteoarthritis, as well as various pain syndromes. , Its selectivity for COX- over COX- within the therapeutic dose…
Read more